IGF::OT::IGF - ORALLY BIOAVAILABLEβ-LACTAM/β-LACTAMASE INHIBITOR COMBINATION FOR BIODEFENSE AND PUBLIC HEALTH.
$48,517,079
| Recipient | VENATORX PHARMACEUTICALS INC UEI MBBKNBU5DCC6 |
|---|---|
| Award ID | HHSN272201600029C |
| Award amount | $48,517,079 |
| Award type | DEFINITIVE CONTRACT |
| Awarding agency | Department of Health and Human Services — National Institutes of Health |
| NAICS | 541711 — RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY |
| PSC | AN12 |
| Set-aside | Unrestricted |
| Start date | Sep 19, 2016 |
| End date | Mar 31, 2026 |
| Place of performance | MALVERN, PA |
| Record updated | Jul 31, 2026 |
View the official award record
More awards won by VENATORX PHARMACEUTICALS INC
VENATORX PHARMACEUTICALS, INC.
Department of Health and Human Services · $131,756,814 · Jul 17, 2019
VENATORX PHARMACEUTICALS: ANTIBIOTIC FOR AMR AND BIOTHREAT PATHOGENS
Department of Health and Human Services · $72,141,707 · Sep 27, 2022
PENICILLIN BINDING PROTEINS IGF::OT::IGF
Department of Defense · $14,716,733 · Aug 28, 2017
Our catalog shows awards with a value or ceiling of $250K+ active within the last 5 years. Need older history or smaller awards? Tell us what you need — we expand by request.
Awards tell you who won. Bids tell you what's next. BidCatch scans 100+ federal, state, and local sources every night and sends the new opportunities matching your trade — before they're awarded to someone else. $0 today for 14 days (card required), then $49.99/month.
Search open bids